Marrow Therapeutics raised $173 million to develop an siRNA-based approach for sickle cell disease and beta thalassemia, aiming to compete with gene therapy and gene editing. The startup says its program is designed to deliver comparable effectiveness with a different risk and access profile, positioning RNA interference as a potentially more scalable alternative. The funding round includes investors such as Scion Life Sciences, venBio, and OrbiMed, signaling strong institutional interest in non-viral, non-editing modalities for hemoglobinopathies. The company’s strategy comes after the FDA approval of gene therapies for sickle cell in December 2023 shifted the competitive landscape, leading some programs to refocus or pause. For the market, Marrow’s pitch is not only about clinical efficacy but also about manufacturability and health-system adoption, where durability of response, administration burden, and long-term safety often determine long-term uptake. Executives will watch for how quickly Marrow can move through clinical milestones and demonstrate target engagement and efficacy in relevant patient subgroups. The announcement also spotlights renewed venture appetite for platform-driven therapeutics where differentiation can come from dosing cadence, treatment setting, and reduced infrastructure requirements compared with one-time gene therapy approaches.
Get the Daily Brief